Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Raltegravir 400 mg Clear all
Withdrawn Phase 3 Interventional

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

NCT00984152
View directory record Official record
Conditions
HIV-1 Infections
Interventions
TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily, TDF/FTC + Efavirenz (Atripla) Once-Daily
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen

NCT00738569
View directory record Official record
Conditions
HIV
Interventions
Raltegravir
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics of Raltegravir in the Gastrointestinal (GI) Tract of Healthy Male Volunteers

NCT01325051
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Raltegravir
Drug
Lead sponsor
Angela Kashuba, PharmD
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

RAL-eve Study: Raltegravir Substitution Study

NCT00523237
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

NCT00858962
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

NCT01285050
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

NCT01330199
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Pharmacokinetic Sampling
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2013 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/zidovudine, Efavirenz, Raltegravir
Drug
Lead sponsor
Westat
Other
Eligibility
16 Years and older · Female only
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Fort Lauderdale, Florida • New Orleans, Louisiana • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

NCT00752856
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Isentress, Atripla
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
6
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 28, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
View directory record Official record
Conditions
HIV Infections
Interventions
MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2010 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 4 Interventional

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

NCT00752037
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir and raltegravir
Drug
Lead sponsor
Saint Michael's Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir + Truvada
Drug
Lead sponsor
David A Wohl, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162
View directory record Official record
Conditions
HIV Infection
Interventions
Elvitegravir, Raltegravir, EVG placebo, RAL placebo, Background regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
94
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 28, 2026, 11:41 AM EDT
Completed No phase listed Observational

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

NCT00977756
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV), Tenofovir (TDF), Etravirine (ETV), Darunavir (DRV), Maraviroc (MVC), Lopinavir/ritonavir (LPV/r)
Drug
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 21 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Rifapentine on Raltegravir

NCT00809718
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir and rifapentine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

NCT00843713
View directory record Official record
Conditions
HIV Infection, Inflammation, Cardiovascular Disease, HIV Infections
Interventions
raltegravir, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid

NCT00729924
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Sep 28, 2026, 11:41 AM EDT
Completed No phase listed Observational

Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women

NCT00961272
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Kristine Patterson, MD
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Not applicable Interventional Results available

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

NCT00525733
View directory record Official record
Conditions
HIV Infections
Interventions
darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 28, 2026, 11:41 AM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 28, 2026, 11:41 AM EDT
Completed No phase listed Observational Results available

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

NCT00851799
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents

NCT00485264
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir poloxamer film coated tablet, Raltegravir chewable tablet, Raltegravir oral granules for suspension (20 mg/mL)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
30 Days to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
29
States / cities
Alhambra, California • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-Exposure Prophylaxis in Health Care Workers

NCT01234116
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 28, 2026, 11:41 AM EDT